Heparin Sodium Pinewood Laboratories (Heparin Sodium)

Heparin Sodium Pinewood Laboratories is indicated for several antithrombotic applications where rapid anticoagulation is required. It is commonly employed in clinical settings to manage and prevent clot‑related disorders.

• Prevention and treatment of venous thromboembolism (VTE)
• Prophylaxis of deep‑vein thrombosis (DVT) and pulmonary embolism (PE) after surgery
• Anticoagulation during cardiac and vascular surgical procedures
• Management of acute coronary syndromes, including unstable angina
• Bridging therapy for patients transitioning between oral anticoagulants

Heparin Sodium may cause a range of adverse reactions, from mild to severe, depending on patient factors and dosing.

Common

• Minor bleeding at injection sites or from mucous membranes
• Small hematomas or bruising
• Transient elevation of liver enzymes
• Mild thrombocytopenia (platelet count decrease)
• Nausea or mild headache

Serious

• Major hemorrhage, including intracranial or gastrointestinal bleeding
• Heparin‑induced thrombocytopenia (HIT) with paradoxical clot formation
• Severe allergic reactions such as anaphylaxis
• Spontaneous spinal or epidural hematoma
• Acute renal impairment secondary to bleeding

Before initiating Heparin Sodium therapy, clinicians should evaluate patient history and monitor relevant parameters to minimize risks.

• Assess for active bleeding, recent surgery, or trauma before use
• Monitor platelet counts regularly to detect heparin‑induced thrombocytopenia
• Adjust dose in patients with renal or hepatic impairment
• Use caution in pregnant or breastfeeding individuals; data are limited
• Avoid concurrent use with other anticoagulants unless specifically indicated
• Conduct baseline and periodic coagulation tests (e.g., aPTT) to guide dosing

Heparin Sodium can interact with several medications, affecting its anticoagulant effect or increasing bleeding risk.

Avoid

• Concurrent use of other anticoagulants (e.g., warfarin, direct oral anticoagulants) without close monitoring
• High‑dose aspirin or non‑steroidal anti‑inflammatory drugs (NSAIDs) that increase bleeding tendency
• Thrombolytic agents such as alteplase or streptokinase

Use with caution

• Antiplatelet agents like clopidogrel or ticagrelor, requiring careful coagulation monitoring
• Selective serotonin reuptake inhibitors (SSRIs) that may impair platelet function
• Glycoprotein IIb/IIIa inhibitors used in cardiac procedures
• Certain antibiotics (e.g., vancomycin) that can potentiate anticoagulant effects